NTT DATA Launches Global Business Unit for Microsoft Cloud to Accelerate Enterprise Transformation in the AI Era
7.8.2025 14:00:00 CEST | Business Wire | Press Release
NTT DATA, a global leader in digital business and technology services, today announced its NTT Data business unit for Microsoft Cloud to meet rising demand for secure, AI-driven enterprise cloud transformation. The global unit brings together NTT DATA’s deep industry and technical expertise in Microsoft Cloud, security and AI solutions to accelerate cloud modernization, scale Agentic AI and navigate complex sovereignty and compliance requirements.
“Our expanded collaboration with Microsoft reflects a shared commitment to helping clients tackle today’s complex business challenges with speed, scale and trust,” said Charlie Li, Head of Cloud and Security Services, NTT DATA, Inc. “Through our global business unit for Microsoft Cloud, we’re bringing together the strengths of both organizations to solve modern problems using advanced cloud and AI technologies, whether it’s modernizing operations, improving how people work and connect, or delivering more intelligent, secure and resilient digital experiences.”
Global NTT Data business unit for Microsoft Cloud: scale and specialization
With a presence across more than 50 countries and a deep bench of Microsoft certified specialists holding 24,000 certifications, the NTT DATA business unit for Microsoft Cloud helps clients accelerate digital transformation globally. This unit brings together technical expertise in cloud-native development, cybersecurity, observability and Agentic AI, while staying closely aligned with Microsoft’s technology roadmap and engineering teams.
Led by Aishwarya Singh, Senior Vice President and Head of the Global Business Unit for Microsoft Cloud, the unit buildson NTT DATA’s longstanding strategic alliance with Microsoft to elevate existing capabilities and expands its global reach, reinforcing NTT DATA’s role as a trusted enterprise transformation partner.
To accelerate adoption, NTT DATA is aligning its sales, pre-sales and delivery teams with Microsoft to help clients design, build, secure, migrate and implement solutions on Microsoft Cloud that deliver measurable business impact across industries and regulated markets.
Core areas of focus include:
- Agentic AI at scale: Helping clients rapidly scale AI agents with Microsoft 365 Copilot and Microsoft Azure AI Foundry enabling real-time voice communications and intelligent orchestration with speed, efficiency and ethical integrity.
- Modern cloud solutions: Supporting organizations in building and updating applications In Microsoft Azure to boost agility, reduce complexity and stay ahead of change.
- Developer acceleration: Empowering Azure developers to accelerate cloud-native development with a microservices library of 500+ industry-accelerators, built on top of NTT DATA’s Industry Cloud platform.
- Enhanced digital experience: Enabling more connected, collaborative workplaces with Microsoft 365 and transforming customer engagement through integrated Microsoft Dynamics 365 Contact Center solutions.
- Sovereign cloud adoption: NTT DATA is one of the few Microsoft partners collaborating on Sovereign Cloud specialization under Microsoft AI Cloud partner program.
Driving agentic AI adoption at scale
Today’s announcement also follows strong momentum for NTT DATA’s recently launched Agentic AI Services for Hyperscaler AI Technologies, built on Azure and Azure AI Foundry. In just 90 days, these services have generated nearly 100 enterprise client opportunities, including Newell Brands.
This interest underscores the growing demand for AI-powered automation, intelligent workflows and seamless enterprise integration and the need for scalable solutions that move AI out of the lab and into production. NTT DATA is also scaling support for multi-agent models by leveraging Azure AI Agent Service on Azure AI Foundry. As a result, NTT DATA can help clients build, manage and orchestrate multi-agent workflows across multiple platforms.
Providing next-generation service delivery
NTT DATA is uniquely positioned to lead cloud-native business transformation in the AI era with deep expertise across Azure, Agentic AI and Industry Cloud ecosystems. Backed by 27 Advanced Specializations, including Security, Data & AI for Azure, Infrastructure, Digital & App Innovation and AI Business Solutions, NTT DATA helps enterprises accelerate big data migration and analysis, scale AI and ML workloads with flexibility and implement cost-effective, composable infrastructures that drive innovation and resilience.
“NTT DATA has played a pivotal role in driving global adoption of Microsoft Azure innovations. This global business unit and our expanded collaboration enables enterprises to integrate AI seamlessly, modernize operations and achieve digital transformation with confidence," said Stephen Boyle, Global Leader, SI & Advisory at Microsoft.
Learn more about NTT DATA and Microsoft here.
About NTT DATA
NTT DATA is a $30+ billion trusted global innovator of business and technology services. We serve 75% of the Fortune Global 100 and are committed to helping clients innovate, optimize and transform for long-term success. As a Global Top Employer, we have diverse experts in more than 50 countries and a robust partner ecosystem of established and start-up companies. Our services include business and technology consulting, data and artificial intelligence, industry solutions, as well as the development, implementation and management of applications, infrastructure and connectivity. We are also one of the leading providers of digital and AI infrastructure in the world. NTT DATA is part of NTT Group, which invests over $3.6 billion each year in R&D to help organizations and society move confidently and sustainably into the digital future.
Visit us at nttdata.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250807490453/en/
Contacts
Lori Bosio
Lori.bosio@nttdata.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom